The main scientific committee of the European Medicines Agency (EMEA) is recommending that two new medicines for use in surgical settings be granted marketing authorisations in Europe. But it has rejected an application for a new therapy to treat an inherited disorder known as Friedreich’s Ataxia. In a third decision, it reversed an earlier negative opinion for an orphan drug for adults with acute myeloid leukaemia.
